Laurel Wealth Advisors LLC Sells 774,971 Shares of IQVIA Holdings Inc. $IQV

Laurel Wealth Advisors LLC lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 99.4% during the third quarter, HoldingsChannel.com reports. The fund owned 4,627 shares of the medical research company’s stock after selling 774,971 shares during the period. Laurel Wealth Advisors LLC’s holdings in IQVIA were worth $879,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IQV. Physician Wealth Advisors Inc. grew its stake in shares of IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares during the period. Westside Investment Management Inc. boosted its stake in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new position in IQVIA during the third quarter worth $36,000. Asset Dedication LLC lifted its holdings in shares of IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 168 shares during the period. Finally, Rothschild Investment LLC boosted its stake in shares of IQVIA by 85.5% in the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after purchasing an additional 124 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research report on Thursday, January 22nd. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Mizuho set a $215.00 target price on shares of IQVIA in a research note on Monday, February 23rd. BMO Capital Markets set a $250.00 price target on IQVIA in a research report on Friday, February 6th. Finally, Barclays cut their price objective on IQVIA from $230.00 to $210.00 and set an “equal weight” rating for the company in a research report on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $231.80.

IQVIA Stock Performance

IQV stock opened at $179.09 on Monday. The stock has a market capitalization of $30.39 billion, a PE ratio of 22.79, a price-to-earnings-growth ratio of 1.72 and a beta of 1.40. The company has a debt-to-equity ratio of 2.09, a current ratio of 0.75 and a quick ratio of 0.75. The company has a 50 day moving average price of $212.19 and a 200 day moving average price of $208.13. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.